GrafTech's stock rallied after its Q3 report showing $140 million in sales and $8.6 million adjusted EBITDA, despite ongoing losses and over $1 billion in net debt. Management anticipates mid-single-digit price increases and $20–$25 million in cost savings, but true profitability depends on achieving 30% price hikes in contracts. The company faces refinancing challenges by 2029, making the investment outlook speculative amid persistent losses and rising debt.
GrafTech's recent financial results provide context for readers; here is the Basic Materials sector market snapshot on Pluang as of Oct 28, 2026 21:32 WIB: Out of 83 priced US stocks, 16 rose and 67 fell. Notable movers include SVM at USD 8.38 with a -2.78% change and a typical hold time of 9 days, USAR at USD 10.12 with a -2.69% change and 80% buy order activity, and SLI at USD 1.47 with a -2.65% change and 100% sell order activity. The most notable figure is the 80% buy order activity for USAR.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
